Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Regulatory
Approvals worldwideDrug spendingDrug targets
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 3 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
976Linked to a medicine page here
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from NICE technology appraisal guidance · Last verified · Editorial standards

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
Recommended or optimised
836
Cancer Drugs Fund or Innovative Medicines Fund
64
Only in research
23
Not recommended
145
Terminated (no company submission)
177

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

Recommended or optimised

836 appraisals, newest first, page 7 of 9
AppraisalMedicine pageNICE recommendationPublishedStatus
Teriflunomide for treating relapsing–remitting multiple sclerosis
NICE TA303
TeriflunomideRecommended22 Jan 2014
Updated 1 Jun 2014
Current
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy
NICE TA301
—Optimised27 Nov 2013Replaced by TA953
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
NICE TA300
—Recommended27 Nov 2013Current
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
NICE TA298
RanibizumabRecommended27 Nov 2013
Updated 20 May 2024
Current
Ocriplasmin for treating vitreomacular traction
NICE TA297
—Optimised23 Oct 2013Current
Aflibercept solution for injection for treating wet age‑related macular degeneration
NICE TA294
AfliberceptRecommended24 Jul 2013Current
Eltrombopag for treating chronic immune thrombocytopenia
NICE TA293
EltrombopagOptimised24 Jul 2013
Updated 26 Oct 2018
Current
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder
NICE TA292
AripiprazoleRecommended24 Jul 2013Current
Mirabegron for treating symptoms of overactive bladder
NICE TA290
MirabegronOptimised26 Jun 2013Current
Dapagliflozin in combination therapy for treating type 2 diabetes
NICE TA288
DapagliflozinRecommended Only in research26 Jun 2013
Updated 23 Nov 2016
Current
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
NICE TA287
RivaroxabanRecommended26 Jun 2013Current
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
NICE TA283
RanibizumabRecommended Optimised22 May 2013
Updated 20 May 2024
Current
Pirfenidone for treating idiopathic pulmonary fibrosis
NICE TA282
PirfenidoneOptimised24 Apr 2013Current
Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs
NICE TA280
AbataceptOptimised24 Apr 2013Replaced by TA375
Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures
NICE TA279
—Recommended24 Apr 2013Current
Omalizumab for treating severe persistent allergic asthma
NICE TA278
OmalizumabRecommended24 Apr 2013Current
Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
NICE TA276
Colistimethate Sodium, TobramycinOptimised Recommended27 Mar 2013Current
Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
NICE TA275
ApixabanRecommended27 Feb 2013
Updated 2 Jul 2021
Current
Ranibizumab for treating diabetic macular oedema
NICE TA274
RanibizumabOptimised27 Feb 2013
Updated 26 Oct 2023
Current
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma
NICE TA269
VemurafenibRecommended12 Dec 2012
Updated 1 Jan 2015
Current
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
NICE TA268
IpilimumabRecommended12 Dec 2012Current
Ivabradine for treating chronic heart failure
NICE TA267
IvabradineRecommended28 Nov 2012Current
Mannitol dry powder for inhalation for treating cystic fibrosis
NICE TA266
—Optimised28 Nov 2012Current
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
NICE TA265
DenosumabRecommended Not recommended24 Oct 2012Current
Alteplase for treating acute ischaemic stroke
NICE TA264
AlteplaseRecommended26 Sep 2012Current
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
NICE TA261
RivaroxabanRecommended25 Jul 2012Current
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
NICE TA260
Botulinum toxin type ARecommended27 Jun 2012Current
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
NICE TA259
Abiraterone acetateRecommended27 Jun 2012
Updated 27 Jul 2016
Current
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
NICE TA258
ErlotinibRecommended27 Jun 2012Current
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
NICE TA256
RivaroxabanRecommended23 May 2012
Updated 2 Jul 2021
Current
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis
NICE TA254
FingolimodRecommended25 Apr 2012Current
Boceprevir for the treatment of genotype 1 chronic hepatitis C
NICE TA253
—Recommended25 Apr 2012Withdrawn
Telaprevir for the treatment of genotype 1 chronic hepatitis C
NICE TA252
—Recommended25 Apr 2012Withdrawn
Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia
NICE TA251
Imatinib, Nilotinib, DasatinibRecommended Not recommended25 Apr 2012Current
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
NICE TA249
Dabigatran EtexilateRecommended15 Mar 2012
Updated 2 Jul 2021
Current
Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes
NICE TA248
ExenatideRecommended22 Feb 2012Current
Tocilizumab for the treatment of rheumatoid arthritis
NICE TA247
TocilizumabRecommended22 Feb 2012Current
Pharmalgen for the treatment of bee and wasp venom allergy
NICE TA246
—Recommended22 Feb 2012Withdrawn
Apixaban for preventing venous thromboembolism after hip or knee replacement surgery
NICE TA245
ApixabanRecommended25 Jan 2012Current
Rituximab for the first-line treatment of stage III-IV follicular lymphoma
NICE TA243
RituximabRecommended25 Jan 2012Current
Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance
NICE TA241
Nilotinib, DasatinibRecommended Not recommended13 Jan 2012Current
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
NICE TA238
TocilizumabRecommended Not recommended14 Dec 2011Current
Ticagrelor for the treatment of acute coronary syndromes
NICE TA236
TicagrelorRecommended26 Oct 2011Current
Mifamurtide for the treatment of osteosarcoma
NICE TA235
MifamurtideRecommended26 Oct 2011Current
Golimumab for the treatment of ankylosing spondylitis
NICE TA233
GolimumabRecommended24 Aug 2011Replaced by TA383
Retigabine for the adjunctive treatment of partial onset seizures in epilepsy
NICE TA232
—Recommended27 Jul 2011Current
Bivalirudin for the treatment of ST-segment-elevation myocardial infarction
NICE TA230
BivalirudinRecommended27 Jul 2011Current
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion
NICE TA229
DexamethasoneRecommended Optimised27 Jul 2011Current
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
NICE TA228
Thalidomide, BortezomibRecommended Optimised27 Jul 2011Current
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma
NICE TA226
RituximabRecommended22 Jun 2011Current
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
NICE TA225
GolimumabOptimised22 Jun 2011Current
Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
NICE TA223
Cilostazol, PentoxifyllineRecommended Not recommended25 May 2011Current
Romiplostim for the treatment of chronic immune thrombocytopenia
NICE TA221
RomiplostimRecommended27 Apr 2011
Updated 26 Oct 2018
Current
Golimumab for the treatment of psoriatic arthritis
NICE TA220
GolimumabRecommended27 Apr 2011Current
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
NICE TA218
AzacitidineRecommended23 Mar 2011Current
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
NICE TA217
Donepezil, Galantamine, MemantineRecommended Optimised23 Mar 2011
Updated 20 Jun 2018
Current
Bendamustine for the first-line treatment of chronic lymphocytic leukaemia
NICE TA216
BendamustineRecommended23 Feb 2011Current
Pazopanib for the first-line treatment of advanced renal cell carcinoma
NICE TA215
PazopanibRecommended23 Feb 2011
Updated 1 Aug 2013
Current
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years
NICE TA213
AripiprazoleRecommended26 Jan 2011Current
Prucalopride for the treatment of chronic constipation in women
NICE TA211
PrucaloprideRecommended15 Dec 2010Current
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
NICE TA210
Clopidogrel, DipyridamoleRecommended Optimised15 Dec 2010Current
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
NICE TA208
TrastuzumabOptimised24 Nov 2010Current
Denosumab for the prevention of osteoporotic fractures in postmenopausal women
NICE TA204
DenosumabOptimised27 Oct 2010Current
Liraglutide for the treatment of type 2 diabetes mellitus
NICE TA203
LiraglutideRecommended Optimised Not recommended27 Oct 2010
Updated 1 Dec 2014
Current
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
NICE TA200
—Recommended22 Sep 2010Current
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
NICE TA199
Etanercept, Infliximab, AdalimumabRecommended25 Aug 2010Current
Tocilizumab for the treatment of rheumatoid arthritis
NICE TA198
TocilizumabOptimised25 Aug 2010Replaced by TA247
Dronedarone for the treatment of non-permanent atrial fibrillation
NICE TA197
—Optimised25 Aug 2010
Updated 1 Dec 2012
Current
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
NICE TA195
Adalimumab, Etanercept, Infliximab, Rituximab, AbataceptOptimised Recommended25 Aug 2010Current
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
NICE TA193
RituximabOptimised Only in research28 Jul 2010Current
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
NICE TA192
GefitinibRecommended28 Jul 2010Current
Capecitabine for the treatment of advanced gastric cancer
NICE TA191
CapecitabineRecommended28 Jul 2010Current
Pemetrexed for the maintenance treatment of non-small-cell lung cancer
NICE TA190
PemetrexedRecommended23 Jun 2010
Updated 10 Aug 2017
Current
Human growth hormone (somatropin) for the treatment of growth failure in children
NICE TA188
SomatropinRecommended26 May 2010Current
Infliximab and adalimumab for the treatment of Crohn's disease
NICE TA187
Infliximab, AdalimumabRecommended19 May 2010Current
Certolizumab pegol for the treatment of rheumatoid arthritis
NICE TA186
Certolizumab PegolOptimised24 Feb 2010Replaced by TA375
Trabectedin for the treatment of advanced soft tissue sarcoma
NICE TA185
TrabectedinRecommended24 Feb 2010
Updated 8 Feb 2021
Current
Topotecan for the treatment of relapsed small-cell lung cancer
NICE TA184
TopotecanRecommended Not recommended25 Nov 2009Current
Topotecan for the treatment of recurrent and stage IVB cervical cancer
NICE TA183
TopotecanRecommended28 Oct 2009Current
Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention
NICE TA182
PrasugrelRecommended28 Oct 2009Replaced by TA317
Pemetrexed for the first-line treatment of non-small-cell lung cancer
NICE TA181
PemetrexedRecommended23 Sep 2009Current
Ustekinumab for treating moderate to severe plaque psoriasis
NICE TA180
UstekinumabRecommended23 Sep 2009
Updated 3 Mar 2017
Current
Sunitinib for the treatment of gastrointestinal stromal tumours
NICE TA179
SunitinibRecommended23 Sep 2009Current
Alitretinoin for the treatment of severe chronic hand eczema
NICE TA177
—Recommended26 Aug 2009Current
Cetuximab for the first-line treatment of metastatic colorectal cancer
NICE TA176
CetuximabRecommended26 Aug 2009Current
Rituximab for the first-line treatment of chronic lymphocytic leukaemia
NICE TA174
RituximabOptimised22 Jul 2009Current
Tenofovir disoproxil for the treatment of chronic hepatitis B
NICE TA173
Tenofovir Disoproxil FumarateRecommended22 Jul 2009Current
Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies
NICE TA171
LenalidomideRecommended18 Jun 2009
Updated 26 Jun 2019
Current
Rivaroxaban for preventing venous thromboembolism after hip or knee replacement surgery
NICE TA170
RivaroxabanRecommended22 Apr 2009Current
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
NICE TA169
SunitinibRecommended25 Mar 2009Current
Amantadine, oseltamivir and zanamivir for the treatment of influenza
NICE TA168
Amantadine, OseltamivirRecommended Not recommended25 Feb 2009Current
Endovascular stent–grafts for the treatment of abdominal aortic aneurysms
NICE TA167
—Recommended Only in research25 Feb 2009Current
Cochlear implants for children and adults with severe to profound deafness
NICE TA166
—Recommended Optimised Not recommended28 Jan 2009Current
Machine perfusion systems and cold static storage of kidneys from deceased donors
NICE TA165
—Recommended28 Jan 2009Current
Febuxostat for the management of hyperuricaemia in people with gout
NICE TA164
FebuxostatRecommended17 Dec 2008Current
Infliximab for acute exacerbations of ulcerative colitis
NICE TA163
InfliximabRecommended17 Dec 2008Current
Erlotinib for the treatment of non-small-cell lung cancer
NICE TA162
ErlotinibRecommended Not recommended26 Nov 2008
Updated 1 Dec 2012
Current
Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
NICE TA161
Alendronate, Etidronate, TeriparatideRecommended Optimised27 Oct 2008
Updated 7 Feb 2018
Current
Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
NICE TA160
Alendronate, EtidronateOptimised Not recommended27 Oct 2008
Updated 7 Feb 2018
Current
Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin
NICE TA159
—Only in research Optimised22 Oct 2008Current

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.